Caris Life Sciences vs Veracyte
CAI and VCYT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAI and VCYT compare
Caris Life Sciences is the larger company, worth 2.4 times as much as Veracyte ($9.7B against $4.0B).
Caris Life Sciences grew revenue faster over the last twelve months (85.4% versus 17.3% for Veracyte).
Veracyte keeps more of each dollar of sales as profit, with a net margin of 20.4% compared with 10.6% at Caris Life Sciences.
Veracyte scores higher on the StockData Score (13 against 8 for Caris Life Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAI | VCYT |
|---|---|---|
| Size and price | ||
| Market cap | $9.7B | $4.0B |
| Share price | $34.33 | $50.01 |
| Change, 1 year | 16.6% | 41.2% |
| Change, 5 years | – | 0.10% |
| Beta (5Y) | 2.10 | 1.69 |
| Employees | 1,846 | 755 |
| StockData Score | ||
| Total score | 8 | 13 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 3 (better) |
| Performance score | 3 | 3 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 35.7× |
| P/S | 9.8× | 7.2× (better) |
| P/B | 16.4× | 2.9× (better) |
| EV/EBITDA | 57.4× | 29.4× (better) |
| P/FCF | 78.3× | 24.2× (better) |
| FCF yield | 1.3% | 4.1% (better) |
| Fair value | $14.85 | $41.65 |
| Margin of safety | −131% | −20.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 85.4% (better) | 17.3% |
| Revenue growth, 5Y average | – | 34.5% |
| Net income growth (TTM) | – | 335% |
| EPS growth (TTM) | – | 324% |
| Profitability | ||
| Gross margin | – | 71.7% |
| Operating margin | 15.5% | 18.8% (better) |
| Net margin | 10.6% | 20.4% (better) |
| FCF margin | 12.5% | 29.5% (better) |
| Return on equity | 20.1% (better) | 8.8% |
| Return on invested capital | 31.0% (better) | 10.0% |
| Financial health | ||
| Debt / equity | 0.66 (better) | 0.00 |
| Net debt / EBITDA | 1.67 | – |
| Interest coverage | 3.3× | – |
| Current ratio | 5.53 | 9.16 (better) |
| Altman Z-score | 8.28 | 25.35 (better) |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.22% | – |
| Shareholder yield | 0.22% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 54.5% | 111% |
| Held by insiders | 64.1% | 1.7% |
| Insider net buying, 12 months | −$27.3M | −$21.0M (better) |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 13.7% | 12.9% |
Go deeper
- CAI stock overview
- CAI income statement
- CAI valuation and score
- VCYT stock overview
- VCYT income statement
- VCYT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.